Infliximab administration effective in the treatment of refractory Kawasaki disease.
Salvatore
S
Accomando
Andrea
A
Liotta
Maria Cristina
MC
Maggio
Francesca
F
Cardella
Giovanni
G
Corsello
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D003231:Conjunctivitis; D018572:Disease-Free Survival; D004351:Drug Resistance; D005076:Exanthema; D005334:Fever; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007167:Immunotherapy; D007223:Infant; D000069285:Infliximab; D008206:Lymphatic Diseases; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D000911:Antibodies, Monoclonal; D016756:Immunoglobulins, Intravenous; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab